PDS Biotechnology CorporationPDSB
Oncology5 cited findings · profile updated 2026-08-20
0.20 USDnot live — refreshed daily
About PDS Biotechnology Corporation
PDS Biotechnology Corporation (PDSB) is engaged in oncology research, with a focus on PDS0301 in metastatic colorectal cancer. In a Phase 2 trial, PDS0301 demonstrated an objective response rate (ORR) by RECIST v1.1 of 77.8% in metastatic colorectal cancer. This compares to a 35% ORR by RECIST v1.1 in the control arm for the same indication.
The trial also reported on extrahepatic progression-free survival (PFS) for PDS0301 in metastatic colorectal cancer, where the median was not reached. In the control arm, the extrahepatic PFS was 8.1 months.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Objective response rate (ORR) by RECIST v1.1 | 77.8% (vs 35% in control arm) for PDS0301 in metastatic colorectal cancer | PDS Biotechnology Corp — SEC 8-K (2026-08-13), p.1 |
| Extrahepatic progression-free survival (PFS) | median not reached (vs 8.1 months in control arm) for PDS0301 in metastatic colorectal cancer | PDS Biotechnology Corp — SEC 8-K (2026-08-13), p.1 |
Key projects
- PDS0301 (metastatic colorectal cancer)
In a Phase 2 trial, PDS0301 in metastatic colorectal cancer achieved an objective response rate (ORR) by RECIST v1.1 of 77.8%, compared to 35% in the control arm.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →